The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study

Background: Immediate breast reconstruction (IBR) is routinely offered to improve quality-of-life for women requiring mastectomy, but there are concerns that more complex surgery may delay adjuvant oncological treatments and compromise long-term outcomes. High-quality evidence is lacking. The iBRA-2 study aimed to investigate the impact of IBR on time to adjuvant therapy. Methods: Consecutive women undergoing mastectomy ± IBR for breast cancer July–December, 2016 were included. Patient demographics, operative, oncological and complication data were collected. Time from last definitive cancer surgery to first adjuvant treatment for patients undergoing mastectomy ± IBR were compared and risk factors associated with delays explored. Results: A total of 2540 patients were recruited from 76 centres; 1008 (39.7%) underwent IBR (implant-only [n = 675, 26.6%]; pedicled flaps [n = 105,4.1%] and free-flaps [n = 228, 8.9%]). Complications requiring re-admission or re-operation were significantly more common in patients undergoing IBR than those receiving mastectomy. Adjuvant chemotherapy or radiotherapy was required by 1235 (48.6%) patients. No clinically significant differences were seen in time to adjuvant therapy between patient groups but major complications irrespective of surgery received were significantly associated with treatment delays. Conclusions: IBR does not result in clinically significant delays to adjuvant therapy, but post-operative complications are associated with treatment delays. Strategies to minimise complications, including careful patient selection, are required to improve outcomes for patients

Uptake and photoinduced degradation of phthalic acid esters (PAEs) in Ulva lactuca highlight its potential application in environmental bioremediation

The bioaccumulation of phthalates was studied in fragments of Ulva lactuca exposed for a maximum of 31 days at different concentrations of a solution of six phthalic acid esters (PAEs). The algal matrix showed rapid uptake since the first sampling, which increased over the time of the experimental period, at the end of which seaweed's bioaccumulation potential was also evaluated. After the uptake, the algal matrix was subjected to UV irradiation in order to verify the removal of the phthalates. PAEs with higher octanol-water partition coefficients (logKow) and molecular weights were preferentially uptaken by U. lactuca in all the exposure experiments. It was observed that both accumulation (biota-sediment accumulation factor (log10BSAF) ranging from 3.75 to 4.02) and photodegradation (higher than 70% removal for all phthalates in 8 h) are more efficient at lower concentration levels. These results suggest the potential use of the algal matrices for environmental bioremediation, in order to mitigate the impact of pollution from ubiquitous pollutants such as PAEs

Environmental Aspect Concerning Phthalates Contamination: Analytical Approaches and Assessment of Biomonitoring in the Aquatic Environment

This review is a survey of recent progress in studies concerning the impact of phthalic acid esters in aquatic organisms. After introducing the classification, properties, sources, fate, and toxic effects related to phthalates, an overview of the techniques of extraction and analysis of these substances is provided. As a result, the general concepts of environmental bioindicators, biomonitoring systems, and other concepts related to phthalate contamination in the aquatic environment are presented. Recent bioaccumulation data of different phthalates are summarised in a table and organised according to the type of organism, tissue, and geographical area of sampling. Bioindicator organisms that are more representative of the different phthalates are highlighted and discussed as along with other variables that may be relevant in the assessment of the environmental pollution of these substances. The final part looks at the environmental perspectives and suggests new directions and research objectives to be achieved in the future

Secondary acute non lymphoid leukemia in patients treated for non Hodgkin's lymphoma: No risk of therapy-related ANLL after PROVECIP schedule

[No abstract available

Toward the Transition of Agricultural Anaerobic Digesters into Multiproduct Biorefineries

Anaerobic digestion allows for the proper management of agro-waste, including manure. Currently, more than 18,000 anaerobic digestion plants are under operation in EU, 80% of which are employed in the rural context. Tariff schemes for power generation from biogas produced during anaerobic digestion of agricultural feedstocks in Germany, Italy and Austria are coming to an end and new approaches are needed to exploit the existing infrastructures. Digesters in the rural context can be implemented and modified to be transformed into sustainable multi-feedstock and multi-purpose biorefineries for the production of energy, nutrients, proteins, bio-chemicals such as carboxylic acids, polyesters and proteins. This paper describes how the transition of agricultural anaerobic digesters into multi-products biorefineries can be achieved and what are the potential benefits originating from the application of a pilot scale platform able to treat cow manure and other crop residues while producing volatile fatty acids, polyhydroxyalkanoates, microbial protein material, hydrogen, methane and a concentrated liquid stream rich in nitrogen, potassium and phosphorus

PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity

Acute promyelocitic leukemia (APL) is characterized by the pathognomonic presence in leukemic blasts of the hybrid protein PML/RARA, that acts as a transcriptional repressor impairing the expression of genes that are critical to myeloid differentiation. Here, we show that primary blasts from APL patients express lower levels of the oncosuppressor protein PTEN, as compared to blast cells from other AML subtypes or normal bone marrow, and demonstrate that PML-RARA directly inhibits PTEN expression. We show that All-Trans Retinoic Acid (ATRA) triggers in APL cells an active chromatin status at the core regulatory region of the PTEN promoter, that allows the binding of the myeloid-regulating transcription factor PU.1, and, in turn, the transcriptional induction of PTEN. ATRA, via PML/RARA degradation, also promotes PTEN nuclear re-localization and decreases expression of the PTEN target Aurora A kinase. In conclusion, our findings support the notion that PTEN is one of the primary targets of PML/RARA in AP

A Specific Monoclonal Antibody (PG-B6) Detects Expression of the BCL-6 Protein in Germinal Center B Cells

The BCL-6 gene is frequently involved in translocations occurring at the 3q27 locus and is rear-ranged in approximately 30% of diffuse large cell lymphomas and in a small fraction of follicular lymphomas. The BCL-6 gene encodes for a Kruppel-type zinc-finger protein, the cell/tissue expression and function of which is unknown. In this study, we describe a new monoclonal anti-body (PG-B6) that is specificaly directed against a fixative-sensitive epitope on the amino-terminal region of the BCL-6protein. By immunocytochemical analysis, BCL-6 localizes in the nucleus where PG-B6 staining gives a microgranular/diffuse pattern with exclusion of the nucleoli. The main reactivity of PG-B6in tonsil and spleen is with the nuclei of germinal center B cells, whereas B cells within the mantle and marginal zones do not express BCL-6. No other lymphoid cells in the tonsil express BCL-6 except for a subset of CD3+/CD4+ intrafollicular and interfollicular T cells. A few lymphoid cells of unknown phenotype express BCL-6 in the thymus. Extra-lymphoid BCL-6 expression includes a weak nuclear positivity of epithelia. In non-Hodgkin's lymphomas, BCL-6 expression parallels that observed in normal lymphoid compartments, eg, expression in germinal center-derived tumors (follicular and diffuse large cell lymphomas), but not in mantle cell and marginal zone lymphomas. In most diffuse large cell lymphomas, the BCL-6 protein is expressed at high levels in cases with or without BCL-6 gene rearrangements. These findings indicate that BCL-6 expression is specifically regulated during B lymphocyte development and suggest that BCL-6 may play a role during B cell differentiation in the germinal center